These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20923033)

  • 1. Androgen deprivation therapy in high-risk prostate cancer.
    Buyyounouski MK
    Oncology (Williston Park); 2010 Aug; 24(9):806, 809. PubMed ID: 20923033
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?
    Fang LC; Merrick GS; Wallner KE
    Oncology (Williston Park); 2010 Aug; 24(9):790-6, 798. PubMed ID: 20923031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
    Schulman CC; Wildschutz TP
    Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risk associated with androgen deprivation therapy.
    Leja MJ; Yeh ET
    Oncology (Williston Park); 2010 Aug; 24(9):799, 803, 806. PubMed ID: 20923032
    [No Abstract]   [Full Text] [Related]  

  • 5. [Review of phase III clinical trials on combined anti-androgen therapies in patients with metastasized prostatic cancer].
    Denis L; Dalesio O; Murphy G
    Prog Urol; 1993 Feb; 3(1):75-85. PubMed ID: 8485599
    [No Abstract]   [Full Text] [Related]  

  • 6. Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate.
    Yano A; Kagawa M; Takeshita H; Okada Y; Morozumi M; Kawakami S
    Int J Urol; 2017 Dec; 24(12):863-865. PubMed ID: 29057511
    [No Abstract]   [Full Text] [Related]  

  • 7. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma.
    Foote JE; Crawford ED
    Semin Urol; 1988 Nov; 6(4):291-302. PubMed ID: 3068767
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone therapy and radiotherapy for intermediate risk prostate cancer.
    Lee I; Sandler H
    Semin Radiat Oncol; 2008 Jan; 18(1):7-14. PubMed ID: 18082583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Madlung A; Simcock M; Ghadjar P
    Cancer; 2011 Aug; 117(15):3532; author reply 3532-3. PubMed ID: 21287542
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined androgen blockade for the treatment of metastatic cancer of the prostate.
    Schellhammer PF
    Urology; 1996 May; 47(5):622-8. PubMed ID: 8650856
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer.
    Roach M
    Cancer; 2014 Jun; 120(11):1620-9. PubMed ID: 24591080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    JAMA Oncol; 2016 Sep; 2(9):1236-8. PubMed ID: 27367418
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer.
    Hennenfent BR
    Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691
    [No Abstract]   [Full Text] [Related]  

  • 16. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?
    Zumsteg ZS; Zelefsky MJ
    Lancet Oncol; 2012 Jun; 13(6):e259-69. PubMed ID: 22652234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association of radiotherapy and hormonotherapy in locally advanced prostate cancer].
    Quero L; Wong-Hee-Kam S; Rivera S; Hennequin C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S30-6. PubMed ID: 22516590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
    Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.